KYTX   $8.54  -2.95% Market Closed After Close 8.56 0.23%

Kyverna Therapeutics, Inc.
Total Cash 346.24M
totalCashPerShare 8.025
EBITDA -78.31M
Total Debt 10.00M
quickRatio 16.913
currentRatio 17.173
Total Revenue
debtToEquity 2.998
Revenue/Share
ROA
ROE
grossProfits
freeCashflow
operatingCashflow -66.48M
earningsGrowth
revenueGrowth
grossMargins 0.0
ebitdaMargins 0.0
operatingMargins 0.0
profitMargins 0.0
enterpriseValue -125.25M
forwardPE -1.2442747
floatShares 22.37M
sharesOutstanding 43.15M
sharesShort 2.49M
sharesShortPriorMonth 2.38M
dateShortInterest
sharesPercentSharesOut 0.06%
heldPercentInsiders 0.11%
heldPercentInstitutions 0.85%
Short Ratio help_outline 5.22%
shortPercentOfFloat 0.08%
impliedSharesOutstanding
bookValue 7.73
Price To Book help_outline 0.63
earningsQuarterlyGrowth
netIncomeToCommon -75.92M
trailingEps -2.12%
forwardEps -3.93%
enterpriseToEbitda 1.60
lastDividendValue
lastDividendDate
currentQuarterEstimate -0.79 3Q 2024
institutionsCount 131
lastUpdated Nov. 2, 2024, 7:08 a.m.